Biofortuna to Use TriLink's CleanAmp dNTPs in PCR Kits
September 14, 2010
Biofortuna to Use TriLink's CleanAmp dNTPs in PCR Kits
Biofortuna is developing unique HLA diagnostic kits that will address the transplantation, blood grouping, disease identification, and pharmacogenetic markets, with the first product line targeting the sequence-specific primer transplantation market.
Full-text access for registered users only.
Existing users login here.
New to GenomeWeb? Register here quickly for free access.
New to GenomeWeb? Register here quickly for free access.
Related Stories
- Biofortuna to Use TriLink dNTPs in Diagnostic PCR Kits
September 16, 2010 / PCR Insider - Trovagene, PerkinElmer Ink Assay Development Deal Targeting Liver Cancer
April 26, 2013 / GenomeWeb Daily News - Cepheid, OHSU Co-developing Cancer MDx Tests for GeneXpert
February 19, 2013 / GenomeWeb Daily News - Qiagen Expands Companion Dx Portfolio with Three Licensing Deals; Exceeds 2012 QiaSymphony Placement Target
January 7, 2013 / GenomeWeb Daily News - Seegene, DuPont Ink MDx Tech Licensing Deal
December 10, 2012 / GenomeWeb Daily News